This is a working overview of 分析证书, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
=== Others === In December 2025, Maduro asked Colombian society, including Colombia's army, to join in defending against any aggression from the US. Gustavo Petro, the president of Colombia, denied the request, stating that no one can order Colombia's armed forces, and later adding that Maduro was a dictator but not a narco-trafficker. Petro has called for a negotiated settlement.
== Organization and administration == The University of Arizona, like its sister institutions Arizona State University and Northern Arizona University, is governed by the Arizona Board of Regents or the ABOR, a 12-member body. Eight volunteer members are appointed by the Governor to staggered eight-year terms; two students serve on the board for two-year appointments, with the first year being a nonvoting apprentice year. The Governor and the Superintendent of Public Instruction serve as voting ex-officio members. The ABOR provides "policy guidance" and oversight to the three major degree-granting universities, as provided for by Title 15 of the Arizona Revised Statutes. Suresh Garimella was named the 23rd president of the U of A on August 9, 2024. Previously, he was the president of the University of Vermont from 2019 to 2024. Garimella has also previously served as the Executive Vice President for Research and Partnerships, a Chief Global Affairs Officer, and was recognized as a Goodson Distinguished Professor of Mechanical Engineering at Purdue University. Garimella replaced Robert C. Robbins, MD. He was named as the lone finalist to succeed as president after Robbins announced his plans to step down at the end of his current contract, or before if a suitable successor was identified, during an ABOR meeting on April 2, 2024.
5-MAPB, also known as 5-(N-methyl-2-aminopropyl)benzofuran, as well as by nicknames such as "MDMA 2.0" and "Gas Station Molly", is an entactogen of the phenethylamine, amphetamine, and benzofuran families related to MDMA ("Ecstasy"). It is an analogue of MDMA in which one of the oxygen atoms of the benzodioxole ring has been replaced with a carbon atom. The drug is said to have the closest-known effects to MDMA of any other MDMA analogue, but is said to be less stimulating in comparison and to have less comedown and hangover. In addition, it is more potent than MDMA and has a longer duration. The drug acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA) similarly to MDMA. It is also an agonist of several serotonin receptors, including the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C receptors. Some notable analogues of 5-MAPB besides MDMA include other benzofurans like 5-APB, 5-MAPDB, and 6-MAPB. 5-MAPB was first encountered as a novel designer drug in 2013 and was described in the scientific literature in 2014. It is said to have been first synthesized in 2009. The drug has been patented by Tactogen for potential use as a medicine to treat psychiatric disorders. It is openly sold as a legal recreational drug in the United States. In addition to its use by itself, 5-MAPB is used as a component of the more closely MDMA-mimicking Borax combo.
=== Consumer behavior === A 2021 study by Adweek and Morning Consult found that 49 percent of TikTok users bought goods or services after seeing them being discussed or promoted on the platform. In 2023, the European Journal of Business and Management Research published a study that found that TikTok users were much more likely to trust products shown in TikTok videos that had high-quality videos, rather than products shown on the platform that were more useful or had lower prices. When products go viral on TikTok, the impact on sales can be significant. Stanley tumblers saw their revenue jump from $73 million in 2019 to $750 million in 2023 after going viral on the platform. Feta cheese sales soared by 200% in 2021 after the baked feta pasta recipe took off. CeraVe's sales increased by over 60% in 2020 as TikTok users turned to the brand during lockdown. Other items, like Cat Crack catnip and Isle of Paradise tanning spray, sold out within days after viral posts. In 2023, TikTok rolled out a shopping feature called TikTok Shop, making it easy for users to buy products directly from a range of sellers. This feature lets businesses sell products directly on the platform, using tools like shoppable ads, product showcases, and creator partnerships to boost sales and connect with their audience in a more native way. Some fashion and beauty brands have even started thinking about how a product could be featured on TikTok before they finish developing it.
Sources: en.wikipedia.org
Some genera of Gram-positive bacteria, such as Bacillus, Clostridium, Sporohalobacter, Anaerobacter, and Heliobacterium, can form highly resistant, dormant structures called endospores. Endospores develop within the cytoplasm of the cell; generally, a single endospore develops in each cell. Each endospore contains a core of DNA and ribosomes surrounded by a cortex layer and protected by a multilayer rigid coat composed of peptidoglycan and a variety of proteins. Endospores show no detectable metabolism and can survive extreme physical and chemical stresses, such as high levels of UV light, gamma radiation, detergents, disinfectants, heat, freezing, pressure, and desiccation. In this dormant state, these organisms may remain viable for millions of years. Endospores even allow bacteria to survive exposure to the vacuum and radiation of outer space, leading to the possibility that bacteria could be distributed throughout the universe by space dust, meteoroids, asteroids, comets, planetoids, or directed panspermia. Endospore-forming bacteria can cause disease; for example, anthrax can be contracted by the inhalation of Bacillus anthracis endospores, and contamination of deep puncture wounds with Clostridium tetani endospores causes tetanus, which, like botulism, is caused by a toxin released by the bacteria that grow from the spores. Clostridioides difficile infection, a common problem in healthcare settings, is caused by spore-forming bacteria.
== Drawbacks == In SEC, mass is not measured so much as the hydrodynamic volume. Themolecular weight can be approximated from SEC data by the relationship between molecular weight and hydrodynamic volume for polystyrene standards. Another drawback is the possibility of interaction between the stationary phase and the analyte. Any interaction leads to a later elution time and thus mimics a smaller analyte size. Band broadening occura by turbulence, thermal diffusion, and friction. Bands also overlap with each other. As a result, the eluent usually gets considerably diluted. A few precautions can be taken to prevent the likelihood of the bands broadening. For instance, one can apply the sample in a narrow, highly concentrated band on the top of the column. The more concentrated the eluent is, the more efficient the procedure would be.
In modern biology, fungaria provide a library of genetic material for DNA barcoding and genomics, allowing scientists to extract and sequence DNA even from centuries-old specimens. Specimen data are increasingly digitized and shared through online portals using data standards such as Darwin Core. As of 2025, an estimated 15 to 20 million preserved fungal specimens exist worldwide, distributed across approximately 3,900 herbaria and fungaria.
=== Cross-linking immunoprecipitation (CLIP) === CLIP analyzes protein interactions with RNA by combining UV cross-linking and immunoprecipitation. CLIP-based techniques are able to map RNA binding protein binding sites of interest on a genome-wide scale. There are many CLIP-based methods including:
=== Edward Burgess === Edward Burgess (David Wilmot) is the crusading editor-in-chief of FinDigest, the financial publication Jim Dycker writes for. Burgess tells Jim that his investigation into Tender's payment laundering does not have enough verifiable evidence, forcing him to run a heavily edited-down version of the piece. Burgess is later forced to fire Jim after an article reveals his collusion with short sellers at SternTao, as well as a sexual assault allegation from Tender assistant Hayley Clay, who Jim had followed to a club and spent the night with. After Jim dies of a drug overdose, Burgess is contacted by Sweetpea Golightly, who tells him that Jim was "more right than he realized" about Tender being fraudulent, and sets up a whistleblower deal for Tony Day, Tender's EMEA CFO who is the face of the company's suspicious acquisitions in the region. However, Burgess and Sweetpea's interview with Day is sabotaged by Whitney, who persuades Day mere minutes before to remain loyal to Tender. Harper later goes to Burgess and has him publish a claim (concocted by Yasmin) that the Labour government suppressed internal concerns about Tender. Burgess reluctantly agrees, and his article is subsequently amplified by Norton's tabloids, opening Tender to a new audit and a fraud investigation.
Sources: en.wikipedia.org
S. affinis is planted as a bulb (vegetative) in spring (March–May). Multiple bulbs are planted 5 to 8 cm (2 to 3+1⁄8 in) deep into a hole of dimensions 30 by 30 cm (12 by 12 in). The plant can achieve a height of 30 cm (12 in). Weeding is necessary but it is important not to damage the root system. A sufficient water supply during summer is important. Harvest is from November to March. It is important that the soil is not frozen when harvesting. The storage of S. affinis tubers is difficult. Because of their thin skin, they can be stored only for a few days, about a week in a fridge. An alternative can be a fresh ongoing harvesting out of humid sand, thereby the tubers stay fresh for several months.
This glossary of cellular and molecular biology is a list of definitions of terms and concepts commonly used in the study of cell biology, molecular biology, and related disciplines, including genetics, biochemistry, and microbiology. It is split across two articles:
=== Research for therapeutic use === The classification of L-serine as a non-essential amino acid has come to be considered as conditional, since vertebrates such as humans cannot always synthesize optimal quantities over entire lifespans. Safety of L-serine has been demonstrated in an FDA-approved human phase I clinical trial with Amyotrophic Lateral Sclerosis, ALS, patients (ClinicalTrials.gov identifier: NCT01835782), but treatment of ALS symptoms has yet to be shown. A 2011 meta-analysis found adjunctive sarcosine to have a medium effect size for negative and total symptoms of schizophrenia. There also is evidence that L‐serine could acquire a therapeutic role in diabetes. D-Serine is being studied in rodents as a potential treatment for schizophrenia. D-Serine also has been described as a potential biomarker for early Alzheimer's disease (AD) diagnosis, due to a relatively high concentration of it in the cerebrospinal fluid of probable AD patients. D-serine, which is made in the brain, has been shown to work as an antagonist/inverse co-agonist of t-NMDA receptors mitigating neuron loss in an animal model of temporal lobe epilepsy. D-Serine has been theorized as a potential treatment for sensorineural hearing disorders such as hearing loss and tinnitus.
=== Pharmaceutical industry === In the pharmaceutical industry, ICP-MS is used for detecting inorganic impurities in pharmaceuticals and their ingredients. New and reduced maximum permitted exposure levels of heavy metals from dietary supplements, introduced in USP (United States Pharmacopeia) «〈232〉Elemental Impurities—Limits» and USP «〈233〉Elemental Impurities—Procedures», will increase the need for ICP-MS technology, where, previously, other analytic methods have been sufficient.
The polymerization cofactor profilin and the ATP·actin combine to form a profilin-ATP-actin complex that then binds to the end-tracking unit The cofactor and monomer are transferred to the barbed-end of an actin already clamped filament The tracking unit and cofactor dissociate from the adjacent protofilament, in a step that can be facilitated by ATP hydrolysis energy to modulate the affinity of the cofactor and/or the tracking unit for the filament; and this mechanoenzymatic cycle is then repeated, starting this time on the other sub-filament growth site. When operating with the benefit of ATP hydrolysis, AC motors generate per-filament forces of 8–9 pN, which is far greater than the per-filament limit of 1–2 pN for motors operating without ATP hydrolysis. The term actoclampin is generic and applies to all actin filament end-tracking molecular motors, irrespective of whether they are driven actively by an ATP-activated mechanism or passively. Some actoclampins (e.g., those involving Ena/VASP proteins, WASP, and N-WASP) apparently require Arp2/3-mediated filament initiation to form the actin polymerization nucleus that is then "loaded" onto the end-tracker before processive motility can commence. To generate a new filament, Arp2/3 requires a "mother" filament, monomeric ATP-actin, and an activating domain from Listeria ActA or the VCA region of N-WASP. The Arp2/3 complex binds to the side of the mother filament, forming a Y-shaped branch having a 70-degree angle with respect to the longitudinal axis of the mother filament.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.